PMID- 32819746
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20201221
IS  - 1532-1940 (Electronic)
IS  - 0266-4356 (Linking)
VI  - 58
IP  - 8
DP  - 2020 Oct
TI  - New mouthwash: an efficacious intervention for oral ulceration associated with 
      Behcet's disease.
PG  - 1034-1039
LID - S0266-4356(20)30370-3 [pii]
LID - 10.1016/j.bjoms.2020.07.027 [doi]
AB  - Topical interventions to treat oral ulcers in Behcet's disease (BD) are crucial 
      to control disease activity and improve patients' quality of life. Our aim was to 
      evaluate the effectiveness of a new BD mouthwash (BD MW) for oral ulceration. A 
      retrospective cross-sectional study was carried out on 261 BD patients (141 
      women, mean (SD) age 39.9 (11.8) years, and 120 men, mean (SD) age 41.141(3.7) 
      years). All were assessed using the oral ulcer severity score (OUSS), oral health 
      quality of life (OHQoL), and the Behcet's disease current activity form (BDCAF). 
      Patients were divided into three groups: one group used the BD MW, one group used 
      a betamethasone mouthwash, and the other used no therapeutic mouthwash. Patients 
      were assessed at three and six months. The OUSS in those using the BD MW was nine 
      times lower than it was in those using betamethasone mouthwash (p=0.001), and 12 
      times lower than it was in the no mouthwash group (p=0.001). Compared with the 
      baseline data, use of the BD MW during the first three months significantly 
      reduced the OUSS, the BDCAF score, and intraoral scarring, and also improved 
      OHQoL (p=0.001, 0.019, 0.012, and 0.001, respectively). Ongoing use of the BD MW 
      after six months significantly improved the OUSS, OHQoL, and intraoral scars, and 
      kept oral and systemic disease activity under control. A total of 20/31 patients 
      reported high levels of satisfaction with its use, and a patients' satisfaction 
      score showed a preference for it. This study confirms the efficacy of the BD MW 
      in patients with recurrent oral ulceration (ROU). It is more efficacious than 
      betamethasone mouthwash used alone.
CI  - Copyright (c) 2020. Published by Elsevier Ltd.
FAU - Senusi, Amal
AU  - Senusi A
AD  - Centre for Oral Immunobiology and Regenerative Medicine, Barts and the London 
      School of Medicine and Dentistry, Queen Mary University of London, UK; Centre for 
      Teaching and Innovation, Institute of Dentistry Barts and the London School of 
      Medicine and Dentistry, Queen Mary University of London, UK. Electronic address: 
      a.a.s.senusi@qmul.ac.uk.
FAU - Kang, Angray
AU  - Kang A
AD  - Centre for Oral Immunobiology and Regenerative Medicine, Barts and the London 
      School of Medicine and Dentistry, Queen Mary University of London, UK. Electronic 
      address: a.s.kang@qmul.ac.uk.
FAU - Buchanan, John A G
AU  - Buchanan JAG
AD  - Centre for Teaching and Innovation, Institute of Dentistry Barts and the London 
      School of Medicine and Dentistry, Queen Mary University of London, UK; Oral 
      Medicine Unit, Institute of Dentistry, Dental Hospital, Royal London Hospital, 
      Barts Health NHS Trust, UK. Electronic address: j.a.g.buchanan@qmul.ac.uk.
FAU - Adesanya, Adebowale
AU  - Adesanya A
AD  - Centre for Oral Immunobiology and Regenerative Medicine, Barts and the London 
      School of Medicine and Dentistry, Queen Mary University of London, UK; Behcet's 
      Centre of Excellence, Royal London Hospital, Barts Health NHS Trust, UK. 
      Electronic address: a.o.adesanya@qmul.ac.uk.
FAU - Aloraini, Ghfren
AU  - Aloraini G
AD  - Centre for Oral Immunobiology and Regenerative Medicine, Barts and the London 
      School of Medicine and Dentistry, Queen Mary University of London, UK. Electronic 
      address: g.aloraini@qmul.ac.uk.
FAU - Stanford, Miles
AU  - Stanford M
AD  - Behcet's Centre of Excellence, Royal London Hospital, Barts Health NHS Trust, UK. 
      Electronic address: m.stanford@kcl.ac.uk.
FAU - Fortune, Farida
AU  - Fortune F
AD  - Centre for Oral Immunobiology and Regenerative Medicine, Barts and the London 
      School of Medicine and Dentistry, Queen Mary University of London, UK; Oral 
      Medicine Unit, Institute of Dentistry, Dental Hospital, Royal London Hospital, 
      Barts Health NHS Trust, UK; Behcet's Centre of Excellence, Royal London Hospital, 
      Barts Health NHS Trust, UK. Electronic address: f.fortune@qmul.ac.uk.
LA  - eng
PT  - Journal Article
DEP - 20200725
PL  - Scotland
TA  - Br J Oral Maxillofac Surg
JT  - The British journal of oral & maxillofacial surgery
JID - 8405235
RN  - 0 (Mouthwashes)
SB  - IM
MH  - *Behcet Syndrome/complications/drug therapy
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Mouthwashes/therapeutic use
MH  - *Oral Ulcer/drug therapy/etiology
MH  - Quality of Life
MH  - Retrospective Studies
OTO - NOTNLM
OT  - BD mouthwash (BD MW)
OT  - Behcet's disease (BD)
OT  - Oral Health Quality of Life (OHQoL)
OT  - Oral ulcer severity score (OUSS)
EDAT- 2020/08/21 06:00
MHDA- 2020/12/22 06:00
CRDT- 2020/08/22 06:00
PHST- 2019/12/06 00:00 [received]
PHST- 2020/07/21 00:00 [accepted]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
PHST- 2020/08/22 06:00 [entrez]
AID - S0266-4356(20)30370-3 [pii]
AID - 10.1016/j.bjoms.2020.07.027 [doi]
PST - ppublish
SO  - Br J Oral Maxillofac Surg. 2020 Oct;58(8):1034-1039. doi: 
      10.1016/j.bjoms.2020.07.027. Epub 2020 Jul 25.